{"gene":"MAP4K1","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":1996,"finding":"HPK1 (MAP4K1) is a novel Ste20-related serine/threonine kinase that activates the JNK/SAPK pathway; it directly binds and phosphorylates MEKK1, and JNK1 activation by HPK1 is blocked by dominant-negative MEKK1 or MKK4/SEK1 mutants, placing HPK1 upstream of MEKK1 and MKK4 in the JNK cascade. Unlike PAK65, HPK1 does not bind Rac1/Cdc42, indicating Rac1/Cdc42-independent activation.","method":"Transfection/overexpression in vivo kinase assays, direct binding/phosphorylation of MEKK1 in vitro, dominant-negative epistasis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro phosphorylation assay, dominant-negative epistasis, replicated across two independent labs (PMID:8824585 and PMID:9003777)","pmids":["8824585"],"is_preprint":false},{"year":1996,"finding":"HPK1 specifically activates the SAPK/JNK pathway (but not p38/RK or ERK) and signals via the SH3-containing mixed lineage kinase MLK-3 and SEK1; a functional HPK1 kinase domain is required for SAPK activation.","method":"Transfection into COS1 cells, dominant-negative epistasis with SEK1 and MLK-3","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — kinase-dead mutant, epistasis experiments, replicated from independent lab","pmids":["9003777"],"is_preprint":false},{"year":1997,"finding":"TAK1 acts as an intermediate in the HPK1→TAK1→MKK4/SEK1→JNK kinase cascade: kinase-defective TAK1 suppresses HPK1-induced JNK activity; dominant-negative MEKK1 and MLK3 do not inhibit TAK1-induced JNK, placing TAK1 specifically between HPK1 and MKK4.","method":"Transient transfection, dominant-negative epistasis, kinase-dead mutants","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple dominant-negative constructs used in epistasis, clear pathway ordering","pmids":["9278437"],"is_preprint":false},{"year":1997,"finding":"Grb2 SH3 domains bind directly to specific proline-rich motifs in the HPK1 C-terminal tail; EGF stimulation recruits the Grb2·HPK1 complex to the autophosphorylated EGF receptor and Shc; activated receptor and cytoplasmic tyrosine kinases (including EGFR) induce tyrosine phosphorylation of HPK1.","method":"In vitro SH3-binding assay, co-immunoprecipitation from transfected Cos1 cells, EGF stimulation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, in vitro binding assay, multiple tyrosine kinases tested","pmids":["9346925"],"is_preprint":false},{"year":1998,"finding":"HPK1 binds selectively to the first SH3 domains of c-Crk and CRKL via proline-rich motifs in its C-terminal non-catalytic region; HPK1 also binds both SH3 domains of Grb2 and weakly to Nck; c-Crk II and CRKL are substrates phosphorylated by HPK1 in vitro.","method":"In vitro SH3-binding assay with >25 SH3 domains, co-immunoprecipitation of endogenous proteins, in vitro kinase assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — comprehensive in vitro binding screen, co-IP of endogenous proteins, in vitro substrate phosphorylation","pmids":["9788432"],"is_preprint":false},{"year":1999,"finding":"HPK1 is cleaved by caspase-3 during apoptosis at the conserved DDVD motif (Asp385); cleavage separates the N-terminal kinase domain from the C-terminal regulatory domain, enhances HPK1 kinase activity, and abolishes binding to adaptor proteins Grb2 and Crk.","method":"In vitro cleavage by recombinant caspase-3, peptide inhibitor blockade, mutational analysis (D385A), in vivo/in vitro cleavage assays, co-immunoprecipitation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with recombinant caspase-3, site-directed mutagenesis identifying cleavage site, multiple orthogonal assays","pmids":["10602493"],"is_preprint":false},{"year":1999,"finding":"HPK1 activates both IKK-α and IKK-β, linking the HPK1-MEKK1 stress response pathway to NF-κB activation; IKK-β phosphorylates IκB constitutively while IKK-α requires stimulation.","method":"Overexpression/co-transfection, kinase activity assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — functional activation assays, but single lab and no in vitro direct kinase assay between HPK1 and IKK","pmids":["10523828"],"is_preprint":false},{"year":2000,"finding":"HPK1 is activated by TCR and BCR engagement; Src and Syk/ZAP-70 tyrosine kinases and adaptor proteins LAT, SLP-76, BLNK, Grb2, and Grap are required for HPK1 activation; overexpressed HPK1 inhibits TCR-induced AP-1 and ERK2 activation (negative regulation), while kinase-inactive HPK1 potentiates these responses.","method":"HPK1 kinase activity assays after receptor engagement, dominant-negative and kinase-dead HPK1 overexpression, co-immunoprecipitation","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — kinase activity measurements, kinase-dead epistasis, multiple adaptor protein co-IPs; replicated aspects by multiple subsequent papers","pmids":["10795738"],"is_preprint":false},{"year":2001,"finding":"HPK1 activates NF-κB through a pathway independent of SAPK/JNK; full-length kinase-active HPK1 is required for NF-κB activation while the isolated kinase domain suffices for SAPK/JNK; dominant-negative IKKβ blocks HPK1-mediated NF-κB activation; caspase cleavage releases the HPK1-C fragment which dominantly inhibits NF-κB (including NIK- and TNFα-induced) by impairing the IKK complex.","method":"Dominant-negative SEK1 and IKKβ epistasis, overexpression of full-length vs. kinase domain and C-terminal fragment, NF-κB reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple dominant-negative constructs, truncation analysis separating NF-κB from JNK pathway, clear mechanistic dissection","pmids":["11278403"],"is_preprint":false},{"year":2001,"finding":"Grap2 (MONA/GADS-related adaptor) interacts with HPK1 in vitro and in Jurkat T cells via its C-terminal SH3 domain binding to the second proline-rich motif of HPK1; co-expression of Grap2 with HPK1 increases HPK1 kinase activity and additively enhances JNK activation and IL-2 promoter activity.","method":"Co-immunoprecipitation from Jurkat cells, kinase activity assay, luciferase reporter","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 3 — co-IP and kinase assay; single lab, moderate mechanistic follow-up","pmids":["11313918"],"is_preprint":false},{"year":2001,"finding":"Clnk (SLP-76 family adaptor) physically associates with HPK1 in hematopoietic cells (identified by yeast two-hybrid and co-transfection), with interaction augmented by immunoreceptor stimulation; kinase-defective HPK1 blocks Clnk-stimulated IL-2 promoter activity, indicating Clnk signals through HPK1.","method":"Yeast two-hybrid, co-transfection co-immunoprecipitation in Cos-1 cells, Jurkat transfection luciferase assay, kinase-dead epistasis","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2-3 — yeast two-hybrid plus co-IP plus functional epistasis, single lab","pmids":["11509653"],"is_preprint":false},{"year":2003,"finding":"PGE2 positively activates HPK1 catalytic activity in hematopoietic cells; ectopic HPK1 negatively regulates PGE2-induced fos gene transcription, identifying HPK1 as a negative regulator of PGE2-GPCR signaling.","method":"HPK1 kinase activity assay after PGE2 treatment, ectopic expression/reporter assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — kinase activity assay, reporter gene assay, single lab","pmids":["12522005"],"is_preprint":false},{"year":2004,"finding":"The Mona/Gads C-terminal SH3 domain (SH3C) binds to an HPK1 proline-rich motif combining an atypical RXXK motif (essential for binding via charge interactions) with a PXXP motif; crystal structure of the complex reveals SH3 domain versatility and a binding mode distinct from SLP-76.","method":"Isothermal titration calorimetry, X-ray crystallography, mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus ITC quantification plus mutagenesis in one study","pmids":["15100220"],"is_preprint":false},{"year":2005,"finding":"HPK1 is a functional component of the endogenous IKK complex in T cells; full-length HPK1 enhances IKKβ phosphorylation and is required for TCR-mediated NF-κB activation; siRNA knockdown of HPK1 blunts NF-κB activation; caspase-cleaved HPK1-C sequesters the inactive IKK complex by binding to IKKα and IKKβ, suppressing NF-κB and sensitizing T cells to AICD.","method":"Co-immunoprecipitation with endogenous IKK complex, siRNA knockdown, HPK1-C transgenic mice, NF-κB reporter assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — endogenous co-IP, siRNA KD, transgenic mouse model, multiple functional assays","pmids":["16341093"],"is_preprint":false},{"year":2006,"finding":"During monocytic differentiation, caspase-3 cleaves HPK1 into the N-terminal HPK1-N fragment (kinase domain), which is constitutively active, sustains JNK activation, phosphorylates Bad, and promotes IL-3-independent progenitor survival and monocytic lineage differentiation.","method":"Primary mouse progenitor cell culture, caspase inhibitor treatment, JNK activity assay, Bad phosphorylation assay","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 — caspase inhibitor functional experiments, kinase activity assays; single lab","pmids":["17024227"],"is_preprint":false},{"year":2007,"finding":"PGE2 activates HPK1 via a cAMP/PKA-dependent pathway that is independent of phosphotyrosine-based signaling (Lck, ZAP-70, SLP-76, LAT) and SH3-mediated adaptor interactions; Ser171 within the activation loop is the PKA phosphorylation site required for this response, as S171A mutation completely abrogates PGE2-induced HPK1 activation; HPK1 fails to respond to PGE2 in PKA-deficient S49 cells.","method":"Kinase activity assay, site-directed mutagenesis (S171A), PKA-deficient S49 cell line, pharmacological dissection","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis identifying specific phosphorylation site, PKA-deficient cell line validation, multiple orthogonal approaches","pmids":["17895239"],"is_preprint":false},{"year":2007,"finding":"Caspase-cleaved HPK1-C selectively blocks NF-κB-dependent antiapoptotic Bcl-2 family member induction but not proapoptotic Bim; T and B lymphocytes from HPK1-C transgenic mice undergo AICD independently of CD95/CD95L via caspase-9; siRNA knockdown of HPK1/HPK1-C reduces AICD.","method":"HPK1-C transgenic mice, siRNA knockdown, Bcl-2 family protein western blotting, flow cytometric apoptosis assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — transgenic mouse model, siRNA, multiple orthogonal readouts; replicates and extends earlier mechanistic work","pmids":["17712048"],"is_preprint":false},{"year":2008,"finding":"After cerebral ischemia, activated Src tyrosine-phosphorylates HPK1 (via NMDA receptor activation), which then activates the MLK3-MKK7-JNK3 pathway promoting neuronal death; PP2 (Src inhibitor) or MK801 (NMDA antagonist) reduced HPK1, MLK3, JNK3, and c-Jun activation and protected neurons.","method":"Immunoprecipitation, immunoblot in rat ischemia/reperfusion model, pharmacological inhibition (PP2, MK801), histology/TUNEL","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2-3 — in vivo animal model with pharmacological inhibition and biochemical readouts; single lab","pmids":["18498770"],"is_preprint":false},{"year":2009,"finding":"HPK1 directly phosphorylates the linker region of CARMA1 at residues S549, S551, and S552 (distinct from PKCθ sites) in a TCR stimulation-dependent manner; CARMA1 S551A or S549A/S551A mutants fail to restore NF-κB activation and IL-2 expression; HPK1 interaction with CARMA1 is TCR-stimulation-dependent.","method":"In vitro kinase assay with CARMA1 linker constructs, site-directed mutagenesis, co-immunoprecipitation, NF-κB reporter in CARMA1-deficient T cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — in vitro phosphorylation assay with mutagenesis identifying sites, functional rescue in CARMA1-deficient T cells","pmids":["19706536"],"is_preprint":false},{"year":2010,"finding":"HPK1 competes with ADAP for SLP-76 binding; HPK1 dampens Rap1 activation downstream of TCR, reducing LFA-1 activity; HPK1-deficient T cells show increased ADAP recruitment to SLP-76, elevated Rap1 activation, and increased adhesion to ICAM-1 and spreading.","method":"HPK1-deficient mouse T cells, co-immunoprecipitation, Rap1 activation assay (RalGDS pulldown), ICAM-1 adhesion assay","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — KO mouse cells, competitive binding mechanism demonstrated by co-IP, Rap1 activation assay","pmids":["20957749"],"is_preprint":false},{"year":2010,"finding":"HPK1 associates with SKAP-HOM in B cells and negatively regulates Rap1-mediated LFA-1 integrin activity; HPK1 knockdown in Wehi 231 B cells elevates Rap1-GTP, increases LFA-1-dependent aggregation and ICAM-1 adhesion, and constitutively phosphorylates FAK, via a PI3K/PLC-independent module involving RIAM.","method":"shRNA knockdown in Wehi 231 cells, HPK1-/- mouse B cell analysis, Rap1 activation assay, adhesion assay, co-immunoprecipitation, FAK phosphorylation","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse cells plus shRNA KD, Rap1 assay, co-IP; single lab","pmids":["20824186"],"is_preprint":false},{"year":2012,"finding":"HPK1 phosphorylates BLNK at threonine 152 after BCR activation, which mediates BLNK/14-3-3 binding; T152-phosphorylated BLNK is ubiquitinated at K37, K38, and K42, leading to BLNK degradation and attenuation of MAPK and IKK activation; HPK1-deficient B cells show hyper-proliferation and hyper-activation of these kinases upon BCR ligation.","method":"HPK1-deficient B cells, co-immunoprecipitation, in vitro kinase assay, mass spectrometry identification of ubiquitination sites, site-directed mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro phosphorylation, KO B cells, MS identification of ubiquitination sites, mutagenesis","pmids":["22334673"],"is_preprint":false},{"year":2013,"finding":"HPK1 is required for CXCL1-induced LFA-1-mediated neutrophil adhesion to ICAM-1 under flow; HPK1 is enriched at the lamellipodium of polarized neutrophil-like cells and colocalizes with mAbp1 and actin; HPK1 constitutively co-immunoprecipitates with mAbp1; Mac-1 affinity regulation is independent of HPK1; HPK1-deficient mice show defective PMN adhesion and extravasation in vivo.","method":"HPK1-deficient mouse neutrophils, intravital microscopy, adhesion assay under flow, co-immunoprecipitation, LFA-1 affinity assay, confocal microscopy","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — KO mouse model with intravital microscopy, in vitro adhesion assay, co-IP, specific localization data linked to function","pmids":["23460610"],"is_preprint":false},{"year":2019,"finding":"PDIA6 interacts with MAP4K1 (HPK1) by co-immunoprecipitation and inhibits MAP4K1 phosphorylation, thereby suppressing the MAP4K1/JNK/c-Jun signaling pathway and reducing cisplatin-induced apoptosis and autophagy in NSCLC cells.","method":"Co-immunoprecipitation, phospho-kinase array, gain/loss-of-function in vitro and in vivo","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 3 — co-IP and kinase phosphorylation assay, single lab, no direct in vitro kinase assay","pmids":["30922965"],"is_preprint":false},{"year":2019,"finding":"Crystal structures of the native HPK1 kinase domain reveal it forms an inactive dimer in the non-phosphorylated state (activation loop of each monomer occupying partner's ATP/substrate-binding site); doubly phosphorylated activation loop adopts an active conformation with reduced dimer interface; phosphomimetic mutant (T165E/S171E) shows an alternative domain-swapped configuration; revealing trans-regulation via dimer formation and remodeling of the activation segment.","method":"X-ray crystallography of HPK1 kinase domain in non-phosphorylated, doubly phosphorylated, and phosphomimetic states complexed with sunitinib (2.17-3.00 Å resolution)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple crystal structures at high resolution with different phosphorylation states, revealing mechanistic basis of activation","pmids":["31018963"],"is_preprint":false},{"year":2020,"finding":"HPK1 mediates T cell dysfunction via the HPK1-NFκB-Blimp1 axis; MAP4K1 knockout mice show slower tumor growth and less exhausted, more proliferative tumor-infiltrating T cells; HPK1 depletion, pharmacological inhibition, or PROTAC-mediated degradation improves CAR-T cell efficacy in preclinical models.","method":"MAP4K1 KO mice, CAR-T cell tumor models, PROTAC degradation, pharmacological inhibition","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — KO mouse models with multiple tumor models, CAR-T functional assays, multiple pharmacological modalities","pmids":["32860752"],"is_preprint":false},{"year":2021,"finding":"MAP4K1 (HPK1) negatively regulates RLR antiviral signaling by interacting with TBK1 (identified by yeast two-hybrid) and promoting K48-linked ubiquitination and proteasomal degradation of TBK1/IKKε via the E3 ubiquitin ligase DTX4; MAP4K1 overexpression inhibits IFN-β production after RNA virus infection, while knockdown/knockout has the opposite effect; DTX4 knockdown abrogates TBK1 ubiquitination.","method":"Yeast two-hybrid, co-immunoprecipitation, overexpression and knockdown/knockout, ubiquitination assay (K48-linkage), proteasome inhibitor treatment","journal":"Microbiology spectrum","confidence":"High","confidence_rationale":"Tier 2 — yeast two-hybrid initial identification, co-IP, ubiquitination assay with linkage specificity, DTX4 epistasis; multiple orthogonal methods","pmids":["34908452"],"is_preprint":false},{"year":2021,"finding":"An allosteric HPK1 inhibitor binds preferentially to unphosphorylated (inactive) full-length HPK1 (>24-fold vs. active HPK1), is non-competitive with ATP, requires domains outside the isolated kinase domain, and attenuates kinase autophosphorylation, revealing an allosteric pocket encompassing residues within and outside the kinase domain.","method":"Kinase cascade assay, ATP-competition assay, isolated kinase domain binding assay, biochemical binding assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1-2 — mechanistic biochemical characterization of allosteric binding mode, domain requirement established by direct comparison","pmids":["34608799"],"is_preprint":false},{"year":2024,"finding":"The HPK1 citron homology domain (CHD) adopts a seven-bladed β-propellor fold that directly binds to the kinase domain (KD); CHD-KD interaction negatively regulates kinase activity; CHD provides protein stability in cells and contributes to docking of the substrate SLP76.","method":"X-ray crystallography (CHD structure), hydrogen-deuterium exchange mass spectrometry, mutagenesis, biochemical binding assays, functional kinase assays, cellular stability assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus HDX-MS plus mutagenesis with functional correlation; multiple orthogonal methods in single study","pmids":["38697971"],"is_preprint":false},{"year":2024,"finding":"HPK1 is aberrantly overexpressed in dysfunctional NK cells; conditional HPK1 overexpression in NK cells exacerbates melanoma lung metastasis; MAP4K1-deficient mice are resistant to metastasis; mechanistically HPK1 restrains NK cell cytotoxicity and expansion via activating receptors; TGF-β1 upregulates HPK1 in NK cells.","method":"Conditional NK cell-specific HPK1 overexpression mouse model, MAP4K1-deficient mice, tumor metastasis assays, NK cytotoxicity assays, activating receptor signaling assays","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 2 — conditional gain-of-function and KO mouse models with specific cellular phenotype readouts","pmids":["38828677"],"is_preprint":false},{"year":2024,"finding":"In glioblastoma cells, MAP4K1 loss down-regulates membrane-bound IL-18R and IL-6R by inhibiting the PI3K-AKT pathway; MAP4K1 restoration rescues IL-18R/IL-6R expression and proliferative responses to IL-18, revealing a cancer cell-intrinsic oncogenic role via the IL-18/IL-18R/PI3K-AKT pathway.","method":"MAP4K1 siRNA knockdown, MAP4K1 restoration rescue, transcriptome analysis, PI3K-AKT pathway western blotting, IL-18 stimulation assays","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2-3 — KD and rescue experiment, pathway-level western blotting; single lab","pmids":["37734869"],"is_preprint":false},{"year":2025,"finding":"HPK1 enhances NF-κB/STAT3/p38-MAPK pathways and gasdermin D cleavage in neutrophils, promoting neutrophil hyperactivation; HPK1 promotes mobilization of CXCR2high bone marrow neutrophils after ischemic stroke; HPK1 loss or pharmacological inhibition reduces neutrophil hyperactivation, NET aggregation, and post-stroke lung/neurological injury.","method":"HPK1-deficient mice, pharmacological HPK1 inhibition, neutrophil activation assays, LPS-stimulated pathway analysis, mouse AIS model","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse and pharmacological inhibition, pathway-level mechanistic readouts; single lab","pmids":["40169896"],"is_preprint":false}],"current_model":"MAP4K1 (HPK1) is a hematopoietic-restricted Ste20-related serine/threonine kinase that functions as a negative immune checkpoint: it is activated downstream of TCR/BCR engagement (via adaptors including Grb2, SLP-76, Gads/Mona, ADAP, Clnk, and Crk) and by PGE2 via a PKA-dependent mechanism (phosphorylating Ser171); activated HPK1 phosphorylates CARMA1 (at S549/S551/S552) to initially promote NF-κB and phosphorylates BLNK (T152) to trigger its ubiquitination and degradation, dampening BCR signaling; it signals through a MEKK1/MLK3→MKK4/SEK1→JNK cascade, and during apoptosis is cleaved by caspase-3 at Asp385, generating an N-terminal fragment with enhanced constitutive kinase activity (sustaining JNK/Bad phosphorylation) and a C-terminal HPK1-C fragment that dominantly inhibits NF-κB by sequestering the IKK complex; structurally, the kinase domain undergoes activation-loop-driven trans-regulation via dimer formation, and the C-terminal citron homology domain folds as a β-propellor that binds the kinase domain to restrain activity and dock substrate SLP76; additionally, HPK1 negatively regulates innate antiviral signaling by recruiting the E3 ligase DTX4 to promote K48-linked ubiquitination and proteasomal degradation of TBK1/IKKε, and competes with ADAP for SLP-76 binding to dampen Rap1-mediated integrin activation in both T cells and B cells."},"narrative":{"teleology":[{"year":1996,"claim":"Identifying HPK1 as a novel Ste20-family kinase that specifically activates the JNK/SAPK pathway via MEKK1 and MLK3→SEK1/MKK4 established the initial signaling cascade framework and distinguished it from Rac/Cdc42-dependent MAP4Ks.","evidence":"Overexpression kinase assays, direct in vitro MEKK1 phosphorylation, dominant-negative epistasis in COS cells","pmids":["8824585","9003777"],"confidence":"High","gaps":["Direct phosphorylation site on MEKK1 not identified","Physiological cell type and upstream stimulus not established"]},{"year":1997,"claim":"Demonstration that TAK1 functions between HPK1 and MKK4 refined the kinase cascade hierarchy, while identification of Grb2 SH3 domain binding to HPK1 proline-rich motifs revealed the first mechanism for receptor-proximal recruitment of HPK1.","evidence":"Dominant-negative epistasis placing TAK1 between HPK1 and MKK4; in vitro SH3 binding and co-IP after EGF stimulation","pmids":["9278437","9346925"],"confidence":"High","gaps":["Whether TAK1 is a direct HPK1 substrate not shown","Functional relevance in hematopoietic cells not yet tested"]},{"year":1999,"claim":"Discovery that caspase-3 cleaves HPK1 at Asp385 during apoptosis, generating a constitutively active kinase fragment and an adaptor-binding-deficient C-terminal fragment, revealed a proteolytic switch that bifurcates HPK1 signaling into pro-apoptotic JNK and anti-NF-κB outputs.","evidence":"In vitro cleavage by recombinant caspase-3, D385A mutagenesis, co-IP loss of Grb2/Crk binding","pmids":["10602493"],"confidence":"High","gaps":["In vivo physiological consequence of cleavage not yet demonstrated","Whether cleavage occurs during normal T cell activation unknown"]},{"year":2000,"claim":"Establishing that HPK1 is activated by TCR/BCR engagement via Src/Syk kinases and adaptors SLP-76/BLNK/LAT, and that kinase-dead HPK1 potentiates TCR signaling, defined HPK1 as a negative feedback regulator of antigen receptor responses.","evidence":"HPK1 kinase activity assays after receptor engagement, kinase-dead dominant-negative effects on AP-1/ERK, co-IP with adaptors","pmids":["10795738"],"confidence":"High","gaps":["Substrates mediating negative regulation not identified","In vivo consequence in knockout animals not yet shown"]},{"year":2001,"claim":"Mechanistic dissection showed that full-length HPK1 activates NF-κB through IKKβ independently of JNK, while the caspase-generated C-terminal fragment dominantly inhibits NF-κB by sequestering the IKK complex, establishing dual roles for intact versus cleaved HPK1.","evidence":"Dominant-negative IKKβ and SEK1 epistasis, truncation analysis, NF-κB reporter assays; endogenous IKK co-IP, siRNA, HPK1-C transgenic mice (2005 follow-up)","pmids":["11278403","16341093"],"confidence":"High","gaps":["Direct HPK1 phosphorylation of IKK subunits not demonstrated","Stoichiometry of HPK1-C sequestration in vivo unclear"]},{"year":2001,"claim":"Identification of additional SH3-containing adaptors Grap2/MONA/Gads and Clnk as HPK1-binding partners expanded the upstream receptor-proximal signaling network connecting immunoreceptors to HPK1 activation.","evidence":"Co-IP from Jurkat cells (Grap2), yeast two-hybrid plus co-IP (Clnk), kinase-dead epistasis on IL-2 promoter","pmids":["11313918","11509653"],"confidence":"Medium","gaps":["Relative contribution of each adaptor not dissected in primary cells","Whether adaptors are redundant or pathway-specific unknown"]},{"year":2007,"claim":"Identification of PKA-mediated phosphorylation of Ser171 as the mechanism for PGE2-induced HPK1 activation defined a tyrosine-kinase-independent activation route, linking prostaglandin/cAMP signaling to HPK1 in immunosuppressive contexts.","evidence":"S171A mutagenesis abolishing PGE2-induced activation, PKA-deficient S49 cell validation, pharmacological dissection","pmids":["17895239"],"confidence":"High","gaps":["Whether PKA directly phosphorylates S171 in vitro not shown with purified components","In vivo relevance to tumor microenvironment PGE2 not tested"]},{"year":2009,"claim":"Identification of CARMA1 as a direct HPK1 substrate (phosphorylated at S549/S551/S552) required for TCR-induced NF-κB activation provided the first substrate-level mechanism for HPK1's role in NF-κB signaling.","evidence":"In vitro kinase assay with CARMA1 linker, site-directed mutagenesis, rescue in CARMA1-deficient T cells","pmids":["19706536"],"confidence":"High","gaps":["Whether CARMA1 phosphorylation is activating or priming for negative regulation not fully resolved","Relationship to HPK1's overall negative regulatory role on T cells needs clarification"]},{"year":2010,"claim":"Discovery that HPK1 competes with ADAP for SLP-76 binding to dampen Rap1 activation and LFA-1-mediated integrin adhesion in both T and B cells established HPK1 as a negative regulator of inside-out integrin signaling.","evidence":"HPK1-deficient mouse T and B cells, competitive co-IP, Rap1-GTP pulldown, ICAM-1 adhesion assays","pmids":["20957749","20824186"],"confidence":"High","gaps":["Whether HPK1 kinase activity or scaffolding is required for this competition not resolved","Relative importance in vivo during immune responses not established"]},{"year":2012,"claim":"Demonstration that HPK1 phosphorylates BLNK at T152, triggering 14-3-3 binding and K48-linked ubiquitination/degradation of BLNK, provided the molecular mechanism for HPK1-mediated attenuation of BCR signaling.","evidence":"In vitro kinase assay, HPK1-KO B cells, mass spectrometry of ubiquitination sites, site-directed mutagenesis","pmids":["22334673"],"confidence":"High","gaps":["E3 ligase responsible for BLNK ubiquitination not identified","Whether analogous phosphodegron mechanism operates for SLP-76 in T cells unknown"]},{"year":2019,"claim":"Crystal structures of the HPK1 kinase domain in non-phosphorylated, phosphorylated, and phosphomimetic states revealed that inactive HPK1 forms a dimer with activation loops blocking partner active sites, and activation-loop phosphorylation disrupts this dimer, establishing the structural basis for trans-regulatory autoinhibition.","evidence":"X-ray crystallography at 2.17–3.00 Å resolution in multiple phosphorylation states","pmids":["31018963"],"confidence":"High","gaps":["Full-length HPK1 structure not determined","How C-terminal domains modulate dimerization unknown at this point"]},{"year":2020,"claim":"Genetic ablation and pharmacological inhibition/PROTAC degradation of HPK1 enhanced anti-tumor T cell responses via the NF-κB–Blimp1 axis, validating HPK1 as an immune checkpoint whose loss prevents T cell exhaustion in tumor models.","evidence":"MAP4K1 KO mice, CAR-T cell tumor models, PROTAC degradation, pharmacological inhibition","pmids":["32860752"],"confidence":"High","gaps":["Optimal therapeutic window and potential autoimmune consequences not addressed","Whether kinase activity or scaffolding drives exhaustion not resolved"]},{"year":2021,"claim":"HPK1 was shown to negatively regulate innate antiviral signaling by recruiting E3 ligase DTX4 to promote K48-linked ubiquitination and proteasomal degradation of TBK1/IKKε, extending HPK1's negative regulatory role beyond adaptive to innate immunity.","evidence":"Yeast two-hybrid, co-IP, ubiquitination assay with K48-linkage specificity, DTX4 knockdown epistasis, KO cells","pmids":["34908452"],"confidence":"High","gaps":["Direct biochemical reconstitution of HPK1-DTX4-TBK1 trimeric complex not performed","Whether HPK1 kinase activity is required for DTX4 recruitment not tested"]},{"year":2024,"claim":"Structural determination of the citron homology domain (CHD) as a β-propeller that binds the kinase domain to restrain activity and dock SLP-76 resolved how the C-terminal region autoinhibits HPK1 and mediates substrate engagement, complementing earlier kinase domain structures.","evidence":"X-ray crystallography of CHD, HDX-MS for KD-CHD interaction, mutagenesis, cellular stability assays","pmids":["38697971","38697971"],"confidence":"High","gaps":["Full-length HPK1 structure with CHD–KD interaction at atomic resolution still lacking","Whether allosteric inhibitors target the CHD-KD interface not determined"]},{"year":2024,"claim":"HPK1 was identified as a negative regulator of NK cell cytotoxicity; conditional overexpression exacerbated melanoma metastasis while KO conferred resistance, broadening HPK1's immune checkpoint role beyond T and B cells to NK cells, with TGF-β1 identified as an upstream inducer.","evidence":"NK cell-specific conditional HPK1 overexpression and KO mice, tumor metastasis models, NK cytotoxicity assays","pmids":["38828677"],"confidence":"High","gaps":["Substrates mediating NK cell suppression not identified","Whether HPK1 operates through same SLP-76/integrin axis in NK cells unclear"]},{"year":null,"claim":"Key unresolved questions include the full-length HPK1 structure capturing CHD-KD intramolecular regulation, identification of the E3 ligase for BLNK degradation, whether kinase activity versus scaffolding drives T cell exhaustion, and whether HPK1 inhibition triggers autoimmunity in therapeutic settings.","evidence":"","pmids":[],"confidence":"Low","gaps":["Full-length HPK1 atomic structure not solved","Kinase-dependent vs. scaffolding-dependent functions not genetically separated in vivo","In vivo autoimmune consequences of chronic HPK1 inhibition not systematically evaluated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,18,21]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[7,19,20,25,26,29]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[8,13,26]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[7,13,24]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,19,21,25,26,29]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[5,14,16]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2,6,8,18,25]}],"complexes":["IKK complex (via HPK1-C sequestration)"],"partners":["MEKK1","SLP76","BLNK","GRB2","CRK","TBK1","DTX4","CARMA1"],"other_free_text":[]},"mechanistic_narrative":"MAP4K1 (HPK1) is a hematopoietic-restricted Ste20-family serine/threonine kinase that functions as a central negative regulator of antigen receptor signaling, integrin activation, and innate immune responses. Activated downstream of TCR/BCR engagement via adaptors SLP-76, BLNK, Grb2, Gads, Crk, and Clnk, and independently by PGE2 through PKA-mediated phosphorylation of Ser171, HPK1 signals through MEKK1/TAK1/MLK3→MKK4→JNK and IKK→NF-κB cascades, while attenuating receptor signaling by phosphorylating BLNK (T152) to trigger its ubiquitination and degradation, competing with ADAP for SLP-76 binding to dampen Rap1/integrin activation, and recruiting DTX4 to promote K48-linked ubiquitination of TBK1/IKKε thereby suppressing type I interferon production [PMID:8824585, PMID:10795738, PMID:22334673, PMID:20957749, PMID:34908452]. During apoptosis, caspase-3 cleavage at Asp385 generates a constitutively active N-terminal kinase fragment that sustains JNK/Bad signaling and a C-terminal fragment that sequesters the IKK complex to inhibit NF-κB and promote activation-induced cell death [PMID:10602493, PMID:11278403, PMID:16341093]. Structurally, the kinase domain forms an inactive dimer regulated by activation-loop trans-phosphorylation, while the C-terminal citron homology domain adopts a β-propeller fold that restrains kinase activity and docks substrate SLP-76; genetic ablation of HPK1 enhances anti-tumor immunity by preventing T cell exhaustion and augmenting NK cell cytotoxicity [PMID:31018963, PMID:38697971, PMID:32860752, PMID:38828677]."},"prefetch_data":{"uniprot":{"accession":"Q92918","full_name":"Mitogen-activated protein kinase kinase kinase kinase 1","aliases":["Hematopoietic progenitor kinase","MAPK/ERK kinase kinase kinase 1","MEK kinase kinase 1","MEKKK 1"],"length_aa":833,"mass_kda":91.3,"function":"Serine/threonine-protein kinase, which plays a role in the response to environmental stress (PubMed:24362026). Appears to act upstream of the JUN N-terminal pathway (PubMed:8824585). Activator of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. MAP4Ks act in parallel to and are partially redundant with STK3/MST2 and STK4/MST2 in the phosphorylation and activation of LATS1/2, and establish MAP4Ks as components of the expanded Hippo pathway (PubMed:26437443). May play a role in hematopoietic lineage decisions and growth regulation (PubMed:24362026, PubMed:8824585). Together with CLNK, it enhances CD3-triggered activation of T-cells and subsequent IL2 production (By similarity)","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/Q92918/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MAP4K1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MAP4K1","total_profiled":1310},"omim":[{"mim_id":"610106","title":"DREBRIN-LIKE; DBNL","url":"https://www.omim.org/entry/610106"},{"mim_id":"601983","title":"MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 1; MAP4K1","url":"https://www.omim.org/entry/601983"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":28.3},{"tissue":"lymphoid tissue","ntpm":55.1}],"url":"https://www.proteinatlas.org/search/MAP4K1"},"hgnc":{"alias_symbol":["HPK1"],"prev_symbol":[]},"alphafold":{"accession":"Q92918","domains":[{"cath_id":"3.30.200.20","chopping":"2-94","consensus_level":"medium","plddt":80.1065,"start":2,"end":94},{"cath_id":"1.10.510.10","chopping":"98-295","consensus_level":"medium","plddt":82.943,"start":98,"end":295}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92918","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92918-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92918-F1-predicted_aligned_error_v6.png","plddt_mean":68.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MAP4K1","jax_strain_url":"https://www.jax.org/strain/search?query=MAP4K1"},"sequence":{"accession":"Q92918","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92918.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92918/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92918"}},"corpus_meta":[{"pmid":"8824585","id":"PMC_8824585","title":"Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade.","date":"1996","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8824585","citation_count":220,"is_preprint":false},{"pmid":"9003777","id":"PMC_9003777","title":"HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9003777","citation_count":205,"is_preprint":false},{"pmid":"9278437","id":"PMC_9278437","title":"Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor beta (TGF-beta)-activated kinase (TAK1), a kinase mediator of TGF beta signal transduction.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9278437","citation_count":169,"is_preprint":false},{"pmid":"32860752","id":"PMC_32860752","title":"Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies.","date":"2020","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/32860752","citation_count":158,"is_preprint":false},{"pmid":"10795738","id":"PMC_10795738","title":"HPK1 is activated by lymphocyte antigen receptors and negatively regulates AP-1.","date":"2000","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10795738","citation_count":115,"is_preprint":false},{"pmid":"30922965","id":"PMC_30922965","title":"PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/30922965","citation_count":84,"is_preprint":false},{"pmid":"9346925","id":"PMC_9346925","title":"SH2/SH3 adaptor proteins can link tyrosine kinases to a Ste20-related protein kinase, HPK1.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9346925","citation_count":74,"is_preprint":false},{"pmid":"33408094","id":"PMC_33408094","title":"Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33408094","citation_count":71,"is_preprint":false},{"pmid":"10602493","id":"PMC_10602493","title":"Caspase-mediated cleavage and functional changes of hematopoietic progenitor kinase 1 (HPK1).","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10602493","citation_count":70,"is_preprint":false},{"pmid":"11278403","id":"PMC_11278403","title":"Caspase-mediated cleavage of hematopoietic progenitor kinase 1 (HPK1) converts an activator of NFkappaB into an inhibitor of NFkappaB.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278403","citation_count":66,"is_preprint":false},{"pmid":"16341093","id":"PMC_16341093","title":"Activation or suppression of NFkappaB by HPK1 determines sensitivity to activation-induced cell death.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16341093","citation_count":64,"is_preprint":false},{"pmid":"15100220","id":"PMC_15100220","title":"Mona/Gads SH3C binding to hematopoietic progenitor kinase 1 (HPK1) combines an atypical SH3 binding motif, R/KXXK, with a classical PXXP motif embedded in a polyproline type II (PPII) helix.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15100220","citation_count":61,"is_preprint":false},{"pmid":"32896273","id":"PMC_32896273","title":"A perspective on HPK1 as a novel immuno-oncology drug target.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/32896273","citation_count":58,"is_preprint":false},{"pmid":"19706536","id":"PMC_19706536","title":"Phosphorylation of CARMA1 by HPK1 is critical for NF-kappaB activation in T cells.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19706536","citation_count":52,"is_preprint":false},{"pmid":"22334673","id":"PMC_22334673","title":"Down-regulation of B cell receptor signaling by hematopoietic progenitor kinase 1 (HPK1)-mediated phosphorylation and ubiquitination of activated B cell linker protein (BLNK).","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22334673","citation_count":52,"is_preprint":false},{"pmid":"21993544","id":"PMC_21993544","title":"hsa-miR-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas.","date":"2011","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/21993544","citation_count":51,"is_preprint":false},{"pmid":"9788432","id":"PMC_9788432","title":"The germinal center kinase (GCK)-related protein kinases HPK1 and KHS are candidates for highly selective signal transducers of Crk family adapter proteins.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9788432","citation_count":51,"is_preprint":false},{"pmid":"36209628","id":"PMC_36209628","title":"The development of small-molecule inhibitors targeting HPK1.","date":"2022","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36209628","citation_count":50,"is_preprint":false},{"pmid":"22477524","id":"PMC_22477524","title":"HPK1 as a novel target for cancer immunotherapy.","date":"2012","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/22477524","citation_count":50,"is_preprint":false},{"pmid":"11313918","id":"PMC_11313918","title":"Leukocyte-specific adaptor protein Grap2 interacts with hematopoietic progenitor kinase 1 (HPK1) to activate JNK signaling pathway in T lymphocytes.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11313918","citation_count":49,"is_preprint":false},{"pmid":"15770651","id":"PMC_15770651","title":"Functional interactions of HPK1 with adaptor proteins.","date":"2005","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15770651","citation_count":46,"is_preprint":false},{"pmid":"33956554","id":"PMC_33956554","title":"Inhibitors of immuno-oncology target HPK1 - a patent review (2016 to 2020).","date":"2021","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/33956554","citation_count":43,"is_preprint":false},{"pmid":"33859804","id":"PMC_33859804","title":"Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.","date":"2021","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/33859804","citation_count":42,"is_preprint":false},{"pmid":"11509653","id":"PMC_11509653","title":"Synergistic regulation of immunoreceptor signaling by SLP-76-related adaptor Clnk and serine/threonine protein kinase HPK-1.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11509653","citation_count":42,"is_preprint":false},{"pmid":"36542759","id":"PMC_36542759","title":"Discovery of Macrocycle-Based HPK1 Inhibitors for T-Cell-Based Immunotherapy.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36542759","citation_count":40,"is_preprint":false},{"pmid":"17712048","id":"PMC_17712048","title":"Caspase-cleaved HPK1 induces CD95L-independent activation-induced cell death in T and B lymphocytes.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17712048","citation_count":40,"is_preprint":false},{"pmid":"10523828","id":"PMC_10523828","title":"Hematopoietic progenitor kinase-1 (HPK1) stress response signaling pathway activates IkappaB kinases (IKK-alpha/beta) and IKK-beta is a developmentally regulated protein kinase.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10523828","citation_count":40,"is_preprint":false},{"pmid":"35059127","id":"PMC_35059127","title":"Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).","date":"2021","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/35059127","citation_count":38,"is_preprint":false},{"pmid":"35188729","id":"PMC_35188729","title":"The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy.","date":"2022","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35188729","citation_count":35,"is_preprint":false},{"pmid":"17895239","id":"PMC_17895239","title":"Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17895239","citation_count":35,"is_preprint":false},{"pmid":"29036198","id":"PMC_29036198","title":"The homeodomain-interacting protein kinase HPK-1 preserves protein homeostasis and longevity through master regulatory control of the HSF-1 chaperone network and TORC1-restricted autophagy in Caenorhabditis elegans.","date":"2017","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29036198","citation_count":35,"is_preprint":false},{"pmid":"22801218","id":"PMC_22801218","title":"Pdcd4 knockdown up-regulates MAP4K1 expression and activation of AP-1 dependent transcription through c-Myc.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22801218","citation_count":33,"is_preprint":false},{"pmid":"33738073","id":"PMC_33738073","title":"Identification of Potent Reverse Indazole Inhibitors for HPK1.","date":"2021","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/33738073","citation_count":33,"is_preprint":false},{"pmid":"17024227","id":"PMC_17024227","title":"Sustained JNK signaling by proteolytically processed HPK1 mediates IL-3 independent survival during monocytic differentiation.","date":"2006","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/17024227","citation_count":33,"is_preprint":false},{"pmid":"12522005","id":"PMC_12522005","title":"Hematopoietic progenitor kinase 1 (HPK1) negatively regulates prostaglandin E2-induced fos gene transcription.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12522005","citation_count":31,"is_preprint":false},{"pmid":"34530056","id":"PMC_34530056","title":"SPIB acts as a tumor suppressor by activating the NFkB and JNK signaling pathways through MAP4K1 in colorectal cancer cells.","date":"2021","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/34530056","citation_count":31,"is_preprint":false},{"pmid":"31591939","id":"PMC_31591939","title":"DLX6-AS1 promotes cell proliferation, migration and EMT of gastric cancer through FUS-regulated MAP4K1.","date":"2019","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31591939","citation_count":30,"is_preprint":false},{"pmid":"31018963","id":"PMC_31018963","title":"Multiple conformational states of the HPK1 kinase domain in complex with sunitinib reveal the structural changes accompanying HPK1 trans-regulation.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31018963","citation_count":26,"is_preprint":false},{"pmid":"23460610","id":"PMC_23460610","title":"Hematopoietic progenitor kinase 1 (HPK1) is required for LFA-1-mediated neutrophil recruitment during the acute inflammatory response.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23460610","citation_count":25,"is_preprint":false},{"pmid":"30870006","id":"PMC_30870006","title":"Long noncoding RNA CDKN2B-AS1 interacts with transcription factor BCL11A to regulate progression of cerebral infarction through mediating MAP4K1 transcription.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30870006","citation_count":22,"is_preprint":false},{"pmid":"37990878","id":"PMC_37990878","title":"Design, Synthesis, and Pharmacological Evaluation of Isoindoline Analogues as New HPK1 Inhibitors.","date":"2023","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37990878","citation_count":21,"is_preprint":false},{"pmid":"39585942","id":"PMC_39585942","title":"Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39585942","citation_count":21,"is_preprint":false},{"pmid":"20957749","id":"PMC_20957749","title":"HPK1 competes with ADAP for SLP-76 binding and via Rap1 negatively affects T-cell adhesion.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20957749","citation_count":20,"is_preprint":false},{"pmid":"36621137","id":"PMC_36621137","title":"Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.","date":"2022","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36621137","citation_count":20,"is_preprint":false},{"pmid":"39084610","id":"PMC_39084610","title":"Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39084610","citation_count":20,"is_preprint":false},{"pmid":"32631900","id":"PMC_32631900","title":"HPK1 Influences Regulatory T Cell Functions.","date":"2020","source":"ImmunoHorizons","url":"https://pubmed.ncbi.nlm.nih.gov/32631900","citation_count":19,"is_preprint":false},{"pmid":"38086239","id":"PMC_38086239","title":"Discovery of highly efficient CRBN-recruiting HPK1-PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling.","date":"2023","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38086239","citation_count":19,"is_preprint":false},{"pmid":"37062169","id":"PMC_37062169","title":"Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.","date":"2023","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37062169","citation_count":19,"is_preprint":false},{"pmid":"30605659","id":"PMC_30605659","title":"The Structure of HPK1 Kinase Domain: To Boldly Go Where No Immuno-Oncology Drugs Have Gone Before.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/30605659","citation_count":19,"is_preprint":false},{"pmid":"20824186","id":"PMC_20824186","title":"HPK1 associates with SKAP-HOM to negatively regulate Rap1-mediated B-lymphocyte adhesion.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20824186","citation_count":19,"is_preprint":false},{"pmid":"38650383","id":"PMC_38650383","title":"Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress.","date":"2024","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/38650383","citation_count":17,"is_preprint":false},{"pmid":"38350360","id":"PMC_38350360","title":"Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody.","date":"2024","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38350360","citation_count":17,"is_preprint":false},{"pmid":"37944847","id":"PMC_37944847","title":"Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models.","date":"2023","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37944847","citation_count":16,"is_preprint":false},{"pmid":"34608799","id":"PMC_34608799","title":"Discovery of an Allosteric, Inactive Conformation-Selective Inhibitor of Full-Length HPK1 Utilizing a Kinase Cascade Assay.","date":"2021","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34608799","citation_count":16,"is_preprint":false},{"pmid":"26791749","id":"PMC_26791749","title":"Homeodomain-Interacting Protein Kinase (HPK-1) regulates stress responses and ageing in C. elegans.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26791749","citation_count":16,"is_preprint":false},{"pmid":"39651809","id":"PMC_39651809","title":"Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39651809","citation_count":16,"is_preprint":false},{"pmid":"34908452","id":"PMC_34908452","title":"The Kinase MAP4K1 Inhibits Cytosolic RNA-Induced Antiviral Signaling by Promoting Proteasomal Degradation of TBK1/IKKε.","date":"2021","source":"Microbiology spectrum","url":"https://pubmed.ncbi.nlm.nih.gov/34908452","citation_count":15,"is_preprint":false},{"pmid":"34166980","id":"PMC_34166980","title":"MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway.","date":"2021","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/34166980","citation_count":15,"is_preprint":false},{"pmid":"37536217","id":"PMC_37536217","title":"Discovery of potent and selective HPK1 inhibitors based on the 2,4-disubstituted pyrimidine scaffold with immune modulatory properties for ameliorating T cell exhaustion.","date":"2023","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37536217","citation_count":14,"is_preprint":false},{"pmid":"39928839","id":"PMC_39928839","title":"Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor.","date":"2025","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39928839","citation_count":14,"is_preprint":false},{"pmid":"35370676","id":"PMC_35370676","title":"Discovery of Novel HPK1 Inhibitors Through Structure-Based Virtual Screening.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35370676","citation_count":13,"is_preprint":false},{"pmid":"39331123","id":"PMC_39331123","title":"Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39331123","citation_count":13,"is_preprint":false},{"pmid":"39446986","id":"PMC_39446986","title":"Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39446986","citation_count":13,"is_preprint":false},{"pmid":"22541691","id":"PMC_22541691","title":"The pan-caspase inhibitor Q-VD-OPh has anti-leukemia effects and can interact with vitamin D analogs to increase HPK1 signaling in AML cells.","date":"2012","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/22541691","citation_count":13,"is_preprint":false},{"pmid":"38828677","id":"PMC_38828677","title":"HPK1 Dysregulation-Associated NK Cell Dysfunction and Defective Expansion Promotes Metastatic Melanoma Progression.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38828677","citation_count":12,"is_preprint":false},{"pmid":"37531921","id":"PMC_37531921","title":"Discovery of quinazoline HPK1 inhibitors with high cellular potency.","date":"2023","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37531921","citation_count":12,"is_preprint":false},{"pmid":"33439152","id":"PMC_33439152","title":"Using yeast surface display to engineer a soluble and crystallizable construct of hematopoietic progenitor kinase 1 (HPK1).","date":"2020","source":"Acta crystallographica. Section F, Structural biology communications","url":"https://pubmed.ncbi.nlm.nih.gov/33439152","citation_count":12,"is_preprint":false},{"pmid":"37106265","id":"PMC_37106265","title":"An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma.","date":"2023","source":"Clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37106265","citation_count":12,"is_preprint":false},{"pmid":"38697971","id":"PMC_38697971","title":"HPK1 citron homology domain regulates phosphorylation of SLP76 and modulates kinase domain interaction dynamics.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38697971","citation_count":11,"is_preprint":false},{"pmid":"37659145","id":"PMC_37659145","title":"Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors.","date":"2023","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37659145","citation_count":11,"is_preprint":false},{"pmid":"36655125","id":"PMC_36655125","title":"Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors.","date":"2022","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/36655125","citation_count":11,"is_preprint":false},{"pmid":"39291002","id":"PMC_39291002","title":"Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1.","date":"2024","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/39291002","citation_count":11,"is_preprint":false},{"pmid":"23904186","id":"PMC_23904186","title":"Homeodomain interacting protein kinase (HPK-1) is required in the soma for robust germline proliferation in C. elegans.","date":"2013","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/23904186","citation_count":11,"is_preprint":false},{"pmid":"22421156","id":"PMC_22421156","title":"Dual role of hematopoietic progenitor kinase 1 (HPK1) as a positive regulator of 1α,25-dihydroxyvitamin D-induced differentiation and cell cycle arrest of AML cells and as a mediator of vitamin D resistance.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/22421156","citation_count":11,"is_preprint":false},{"pmid":"37734869","id":"PMC_37734869","title":"Glioblastoma cellular MAP4K1 facilitates tumor growth and disrupts T effector cell infiltration.","date":"2023","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/37734869","citation_count":10,"is_preprint":false},{"pmid":"36655134","id":"PMC_36655134","title":"Potent and Selective Biaryl Amide Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).","date":"2022","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/36655134","citation_count":10,"is_preprint":false},{"pmid":"39563821","id":"PMC_39563821","title":"Design, Synthesis, and Biological Evaluation of a Series of Spiro Analogues as Novel HPK1 Inhibitors.","date":"2024","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/39563821","citation_count":10,"is_preprint":false},{"pmid":"39369461","id":"PMC_39369461","title":"Opportunities and challenges for targeting HPK1 in cancer immunotherapy.","date":"2024","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39369461","citation_count":9,"is_preprint":false},{"pmid":"38795581","id":"PMC_38795581","title":"Design, synthesis, and biological evaluation of 2,4-diaminopyrimidine derivatives as potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors.","date":"2024","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38795581","citation_count":9,"is_preprint":false},{"pmid":"38479166","id":"PMC_38479166","title":"Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors.","date":"2024","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38479166","citation_count":8,"is_preprint":false},{"pmid":"39303515","id":"PMC_39303515","title":"Discovery of 1(2H)-phthalazinone and 1(2H)-isoquinolinone derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.","date":"2024","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39303515","citation_count":8,"is_preprint":false},{"pmid":"39826501","id":"PMC_39826501","title":"Discovery of 1,2,4-benzotriazine derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors.","date":"2025","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39826501","citation_count":7,"is_preprint":false},{"pmid":"39874881","id":"PMC_39874881","title":"Design, Synthesis, and biological evaluation of 7H-Pyrrolo[2,3-d]pyrimidines as potent HPK1 kinase inhibitors.","date":"2025","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39874881","citation_count":6,"is_preprint":false},{"pmid":"30022229","id":"PMC_30022229","title":"Identification of proteins regulated by acid adaptation related two component system HPK1/RR1 in Lactobacillus delbrueckii subsp. bulgaricus.","date":"2018","source":"Archives of microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/30022229","citation_count":6,"is_preprint":false},{"pmid":"39582317","id":"PMC_39582317","title":"An updated review of small-molecule HPK1 kinase inhibitors (2016-present).","date":"2024","source":"Future medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39582317","citation_count":5,"is_preprint":false},{"pmid":"39299176","id":"PMC_39299176","title":"Design, synthesis, and biological evaluation of novel HPK1 inhibitors possessing 3-cyano-quinoline moiety.","date":"2024","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39299176","citation_count":5,"is_preprint":false},{"pmid":"38685185","id":"PMC_38685185","title":"Pharmacological inhibition of HPK1 synergizes with PD-L1 blockade to provoke antitumor immunity against tumors with low antigenicity.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/38685185","citation_count":5,"is_preprint":false},{"pmid":"40738757","id":"PMC_40738757","title":"Discovery of a Novel Potent and Orally Efficacious PROTAC Degrader of HPK1 for Tumor Immunotherapy.","date":"2025","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40738757","citation_count":4,"is_preprint":false},{"pmid":"18498770","id":"PMC_18498770","title":"Tyrosine phosphorylation of HPK1 by activated Src promotes ischemic brain injury in rat hippocampal CA1 region.","date":"2008","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/18498770","citation_count":4,"is_preprint":false},{"pmid":"39981246","id":"PMC_39981246","title":"HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39981246","citation_count":4,"is_preprint":false},{"pmid":"39950624","id":"PMC_39950624","title":"Updated patent review for hematopoietic progenitor kinase (HPK1) inhibitors and degraders (2021-present).","date":"2025","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/39950624","citation_count":3,"is_preprint":false},{"pmid":"40738502","id":"PMC_40738502","title":"Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade.","date":"2025","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40738502","citation_count":3,"is_preprint":false},{"pmid":"25832533","id":"PMC_25832533","title":"[Interactions between MAP4K1 and adaptor proteins].","date":"2015","source":"Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25832533","citation_count":3,"is_preprint":false},{"pmid":"36768974","id":"PMC_36768974","title":"Theoretical Studies on Selectivity of HPK1/JAK1 Inhibitors by Molecular Dynamics Simulations and Free Energy Calculations.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36768974","citation_count":2,"is_preprint":false},{"pmid":"35099066","id":"PMC_35099066","title":"Decoding the signaling profile of hematopoietic progenitor kinase 1 (HPK1) in innate immunity: A proteomic approach.","date":"2022","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35099066","citation_count":2,"is_preprint":false},{"pmid":"40902512","id":"PMC_40902512","title":"Design, synthesis, and biological evaluation of 2-substituted-pyridin-4-yl macrocyclic derivatives as new selective HPK1 inhibitors.","date":"2025","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40902512","citation_count":2,"is_preprint":false},{"pmid":"40494219","id":"PMC_40494219","title":"Design, synthesis and structure-activity relationship studies of novel macrocyclic 2,4-diaminopyrimidines as HPK1 inhibitors.","date":"2025","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40494219","citation_count":2,"is_preprint":false},{"pmid":"23682030","id":"PMC_23682030","title":"Gimme a brake: HPK1 regulates LFA-1 and neutrophil traction.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23682030","citation_count":2,"is_preprint":false},{"pmid":"41417897","id":"PMC_41417897","title":"MAP4K1 and MAP4K2 regulate ABA-induced and Ca2+-mediated stomatal closure in Arabidopsis.","date":"2025","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/41417897","citation_count":1,"is_preprint":false},{"pmid":"40169896","id":"PMC_40169896","title":"Targeting HPK1 inhibits neutrophil responses to mitigate post-stroke lung and cerebral injuries.","date":"2025","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40169896","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46234,"output_tokens":8245,"usd":0.131189},"stage2":{"model":"claude-opus-4-6","input_tokens":12101,"output_tokens":4079,"usd":0.24372},"total_usd":0.374909,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"HPK1 (MAP4K1) is a novel Ste20-related serine/threonine kinase that activates the JNK/SAPK pathway; it directly binds and phosphorylates MEKK1, and JNK1 activation by HPK1 is blocked by dominant-negative MEKK1 or MKK4/SEK1 mutants, placing HPK1 upstream of MEKK1 and MKK4 in the JNK cascade. Unlike PAK65, HPK1 does not bind Rac1/Cdc42, indicating Rac1/Cdc42-independent activation.\",\n      \"method\": \"Transfection/overexpression in vivo kinase assays, direct binding/phosphorylation of MEKK1 in vitro, dominant-negative epistasis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro phosphorylation assay, dominant-negative epistasis, replicated across two independent labs (PMID:8824585 and PMID:9003777)\",\n      \"pmids\": [\"8824585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"HPK1 specifically activates the SAPK/JNK pathway (but not p38/RK or ERK) and signals via the SH3-containing mixed lineage kinase MLK-3 and SEK1; a functional HPK1 kinase domain is required for SAPK activation.\",\n      \"method\": \"Transfection into COS1 cells, dominant-negative epistasis with SEK1 and MLK-3\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — kinase-dead mutant, epistasis experiments, replicated from independent lab\",\n      \"pmids\": [\"9003777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TAK1 acts as an intermediate in the HPK1→TAK1→MKK4/SEK1→JNK kinase cascade: kinase-defective TAK1 suppresses HPK1-induced JNK activity; dominant-negative MEKK1 and MLK3 do not inhibit TAK1-induced JNK, placing TAK1 specifically between HPK1 and MKK4.\",\n      \"method\": \"Transient transfection, dominant-negative epistasis, kinase-dead mutants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple dominant-negative constructs used in epistasis, clear pathway ordering\",\n      \"pmids\": [\"9278437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Grb2 SH3 domains bind directly to specific proline-rich motifs in the HPK1 C-terminal tail; EGF stimulation recruits the Grb2·HPK1 complex to the autophosphorylated EGF receptor and Shc; activated receptor and cytoplasmic tyrosine kinases (including EGFR) induce tyrosine phosphorylation of HPK1.\",\n      \"method\": \"In vitro SH3-binding assay, co-immunoprecipitation from transfected Cos1 cells, EGF stimulation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, in vitro binding assay, multiple tyrosine kinases tested\",\n      \"pmids\": [\"9346925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"HPK1 binds selectively to the first SH3 domains of c-Crk and CRKL via proline-rich motifs in its C-terminal non-catalytic region; HPK1 also binds both SH3 domains of Grb2 and weakly to Nck; c-Crk II and CRKL are substrates phosphorylated by HPK1 in vitro.\",\n      \"method\": \"In vitro SH3-binding assay with >25 SH3 domains, co-immunoprecipitation of endogenous proteins, in vitro kinase assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — comprehensive in vitro binding screen, co-IP of endogenous proteins, in vitro substrate phosphorylation\",\n      \"pmids\": [\"9788432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HPK1 is cleaved by caspase-3 during apoptosis at the conserved DDVD motif (Asp385); cleavage separates the N-terminal kinase domain from the C-terminal regulatory domain, enhances HPK1 kinase activity, and abolishes binding to adaptor proteins Grb2 and Crk.\",\n      \"method\": \"In vitro cleavage by recombinant caspase-3, peptide inhibitor blockade, mutational analysis (D385A), in vivo/in vitro cleavage assays, co-immunoprecipitation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with recombinant caspase-3, site-directed mutagenesis identifying cleavage site, multiple orthogonal assays\",\n      \"pmids\": [\"10602493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HPK1 activates both IKK-α and IKK-β, linking the HPK1-MEKK1 stress response pathway to NF-κB activation; IKK-β phosphorylates IκB constitutively while IKK-α requires stimulation.\",\n      \"method\": \"Overexpression/co-transfection, kinase activity assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional activation assays, but single lab and no in vitro direct kinase assay between HPK1 and IKK\",\n      \"pmids\": [\"10523828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"HPK1 is activated by TCR and BCR engagement; Src and Syk/ZAP-70 tyrosine kinases and adaptor proteins LAT, SLP-76, BLNK, Grb2, and Grap are required for HPK1 activation; overexpressed HPK1 inhibits TCR-induced AP-1 and ERK2 activation (negative regulation), while kinase-inactive HPK1 potentiates these responses.\",\n      \"method\": \"HPK1 kinase activity assays after receptor engagement, dominant-negative and kinase-dead HPK1 overexpression, co-immunoprecipitation\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — kinase activity measurements, kinase-dead epistasis, multiple adaptor protein co-IPs; replicated aspects by multiple subsequent papers\",\n      \"pmids\": [\"10795738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"HPK1 activates NF-κB through a pathway independent of SAPK/JNK; full-length kinase-active HPK1 is required for NF-κB activation while the isolated kinase domain suffices for SAPK/JNK; dominant-negative IKKβ blocks HPK1-mediated NF-κB activation; caspase cleavage releases the HPK1-C fragment which dominantly inhibits NF-κB (including NIK- and TNFα-induced) by impairing the IKK complex.\",\n      \"method\": \"Dominant-negative SEK1 and IKKβ epistasis, overexpression of full-length vs. kinase domain and C-terminal fragment, NF-κB reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple dominant-negative constructs, truncation analysis separating NF-κB from JNK pathway, clear mechanistic dissection\",\n      \"pmids\": [\"11278403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Grap2 (MONA/GADS-related adaptor) interacts with HPK1 in vitro and in Jurkat T cells via its C-terminal SH3 domain binding to the second proline-rich motif of HPK1; co-expression of Grap2 with HPK1 increases HPK1 kinase activity and additively enhances JNK activation and IL-2 promoter activity.\",\n      \"method\": \"Co-immunoprecipitation from Jurkat cells, kinase activity assay, luciferase reporter\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — co-IP and kinase assay; single lab, moderate mechanistic follow-up\",\n      \"pmids\": [\"11313918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Clnk (SLP-76 family adaptor) physically associates with HPK1 in hematopoietic cells (identified by yeast two-hybrid and co-transfection), with interaction augmented by immunoreceptor stimulation; kinase-defective HPK1 blocks Clnk-stimulated IL-2 promoter activity, indicating Clnk signals through HPK1.\",\n      \"method\": \"Yeast two-hybrid, co-transfection co-immunoprecipitation in Cos-1 cells, Jurkat transfection luciferase assay, kinase-dead epistasis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — yeast two-hybrid plus co-IP plus functional epistasis, single lab\",\n      \"pmids\": [\"11509653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PGE2 positively activates HPK1 catalytic activity in hematopoietic cells; ectopic HPK1 negatively regulates PGE2-induced fos gene transcription, identifying HPK1 as a negative regulator of PGE2-GPCR signaling.\",\n      \"method\": \"HPK1 kinase activity assay after PGE2 treatment, ectopic expression/reporter assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — kinase activity assay, reporter gene assay, single lab\",\n      \"pmids\": [\"12522005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The Mona/Gads C-terminal SH3 domain (SH3C) binds to an HPK1 proline-rich motif combining an atypical RXXK motif (essential for binding via charge interactions) with a PXXP motif; crystal structure of the complex reveals SH3 domain versatility and a binding mode distinct from SLP-76.\",\n      \"method\": \"Isothermal titration calorimetry, X-ray crystallography, mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus ITC quantification plus mutagenesis in one study\",\n      \"pmids\": [\"15100220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"HPK1 is a functional component of the endogenous IKK complex in T cells; full-length HPK1 enhances IKKβ phosphorylation and is required for TCR-mediated NF-κB activation; siRNA knockdown of HPK1 blunts NF-κB activation; caspase-cleaved HPK1-C sequesters the inactive IKK complex by binding to IKKα and IKKβ, suppressing NF-κB and sensitizing T cells to AICD.\",\n      \"method\": \"Co-immunoprecipitation with endogenous IKK complex, siRNA knockdown, HPK1-C transgenic mice, NF-κB reporter assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — endogenous co-IP, siRNA KD, transgenic mouse model, multiple functional assays\",\n      \"pmids\": [\"16341093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"During monocytic differentiation, caspase-3 cleaves HPK1 into the N-terminal HPK1-N fragment (kinase domain), which is constitutively active, sustains JNK activation, phosphorylates Bad, and promotes IL-3-independent progenitor survival and monocytic lineage differentiation.\",\n      \"method\": \"Primary mouse progenitor cell culture, caspase inhibitor treatment, JNK activity assay, Bad phosphorylation assay\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — caspase inhibitor functional experiments, kinase activity assays; single lab\",\n      \"pmids\": [\"17024227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PGE2 activates HPK1 via a cAMP/PKA-dependent pathway that is independent of phosphotyrosine-based signaling (Lck, ZAP-70, SLP-76, LAT) and SH3-mediated adaptor interactions; Ser171 within the activation loop is the PKA phosphorylation site required for this response, as S171A mutation completely abrogates PGE2-induced HPK1 activation; HPK1 fails to respond to PGE2 in PKA-deficient S49 cells.\",\n      \"method\": \"Kinase activity assay, site-directed mutagenesis (S171A), PKA-deficient S49 cell line, pharmacological dissection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis identifying specific phosphorylation site, PKA-deficient cell line validation, multiple orthogonal approaches\",\n      \"pmids\": [\"17895239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Caspase-cleaved HPK1-C selectively blocks NF-κB-dependent antiapoptotic Bcl-2 family member induction but not proapoptotic Bim; T and B lymphocytes from HPK1-C transgenic mice undergo AICD independently of CD95/CD95L via caspase-9; siRNA knockdown of HPK1/HPK1-C reduces AICD.\",\n      \"method\": \"HPK1-C transgenic mice, siRNA knockdown, Bcl-2 family protein western blotting, flow cytometric apoptosis assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic mouse model, siRNA, multiple orthogonal readouts; replicates and extends earlier mechanistic work\",\n      \"pmids\": [\"17712048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"After cerebral ischemia, activated Src tyrosine-phosphorylates HPK1 (via NMDA receptor activation), which then activates the MLK3-MKK7-JNK3 pathway promoting neuronal death; PP2 (Src inhibitor) or MK801 (NMDA antagonist) reduced HPK1, MLK3, JNK3, and c-Jun activation and protected neurons.\",\n      \"method\": \"Immunoprecipitation, immunoblot in rat ischemia/reperfusion model, pharmacological inhibition (PP2, MK801), histology/TUNEL\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vivo animal model with pharmacological inhibition and biochemical readouts; single lab\",\n      \"pmids\": [\"18498770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"HPK1 directly phosphorylates the linker region of CARMA1 at residues S549, S551, and S552 (distinct from PKCθ sites) in a TCR stimulation-dependent manner; CARMA1 S551A or S549A/S551A mutants fail to restore NF-κB activation and IL-2 expression; HPK1 interaction with CARMA1 is TCR-stimulation-dependent.\",\n      \"method\": \"In vitro kinase assay with CARMA1 linker constructs, site-directed mutagenesis, co-immunoprecipitation, NF-κB reporter in CARMA1-deficient T cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro phosphorylation assay with mutagenesis identifying sites, functional rescue in CARMA1-deficient T cells\",\n      \"pmids\": [\"19706536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"HPK1 competes with ADAP for SLP-76 binding; HPK1 dampens Rap1 activation downstream of TCR, reducing LFA-1 activity; HPK1-deficient T cells show increased ADAP recruitment to SLP-76, elevated Rap1 activation, and increased adhesion to ICAM-1 and spreading.\",\n      \"method\": \"HPK1-deficient mouse T cells, co-immunoprecipitation, Rap1 activation assay (RalGDS pulldown), ICAM-1 adhesion assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse cells, competitive binding mechanism demonstrated by co-IP, Rap1 activation assay\",\n      \"pmids\": [\"20957749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"HPK1 associates with SKAP-HOM in B cells and negatively regulates Rap1-mediated LFA-1 integrin activity; HPK1 knockdown in Wehi 231 B cells elevates Rap1-GTP, increases LFA-1-dependent aggregation and ICAM-1 adhesion, and constitutively phosphorylates FAK, via a PI3K/PLC-independent module involving RIAM.\",\n      \"method\": \"shRNA knockdown in Wehi 231 cells, HPK1-/- mouse B cell analysis, Rap1 activation assay, adhesion assay, co-immunoprecipitation, FAK phosphorylation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse cells plus shRNA KD, Rap1 assay, co-IP; single lab\",\n      \"pmids\": [\"20824186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HPK1 phosphorylates BLNK at threonine 152 after BCR activation, which mediates BLNK/14-3-3 binding; T152-phosphorylated BLNK is ubiquitinated at K37, K38, and K42, leading to BLNK degradation and attenuation of MAPK and IKK activation; HPK1-deficient B cells show hyper-proliferation and hyper-activation of these kinases upon BCR ligation.\",\n      \"method\": \"HPK1-deficient B cells, co-immunoprecipitation, in vitro kinase assay, mass spectrometry identification of ubiquitination sites, site-directed mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro phosphorylation, KO B cells, MS identification of ubiquitination sites, mutagenesis\",\n      \"pmids\": [\"22334673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HPK1 is required for CXCL1-induced LFA-1-mediated neutrophil adhesion to ICAM-1 under flow; HPK1 is enriched at the lamellipodium of polarized neutrophil-like cells and colocalizes with mAbp1 and actin; HPK1 constitutively co-immunoprecipitates with mAbp1; Mac-1 affinity regulation is independent of HPK1; HPK1-deficient mice show defective PMN adhesion and extravasation in vivo.\",\n      \"method\": \"HPK1-deficient mouse neutrophils, intravital microscopy, adhesion assay under flow, co-immunoprecipitation, LFA-1 affinity assay, confocal microscopy\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse model with intravital microscopy, in vitro adhesion assay, co-IP, specific localization data linked to function\",\n      \"pmids\": [\"23460610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PDIA6 interacts with MAP4K1 (HPK1) by co-immunoprecipitation and inhibits MAP4K1 phosphorylation, thereby suppressing the MAP4K1/JNK/c-Jun signaling pathway and reducing cisplatin-induced apoptosis and autophagy in NSCLC cells.\",\n      \"method\": \"Co-immunoprecipitation, phospho-kinase array, gain/loss-of-function in vitro and in vivo\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — co-IP and kinase phosphorylation assay, single lab, no direct in vitro kinase assay\",\n      \"pmids\": [\"30922965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structures of the native HPK1 kinase domain reveal it forms an inactive dimer in the non-phosphorylated state (activation loop of each monomer occupying partner's ATP/substrate-binding site); doubly phosphorylated activation loop adopts an active conformation with reduced dimer interface; phosphomimetic mutant (T165E/S171E) shows an alternative domain-swapped configuration; revealing trans-regulation via dimer formation and remodeling of the activation segment.\",\n      \"method\": \"X-ray crystallography of HPK1 kinase domain in non-phosphorylated, doubly phosphorylated, and phosphomimetic states complexed with sunitinib (2.17-3.00 Å resolution)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple crystal structures at high resolution with different phosphorylation states, revealing mechanistic basis of activation\",\n      \"pmids\": [\"31018963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HPK1 mediates T cell dysfunction via the HPK1-NFκB-Blimp1 axis; MAP4K1 knockout mice show slower tumor growth and less exhausted, more proliferative tumor-infiltrating T cells; HPK1 depletion, pharmacological inhibition, or PROTAC-mediated degradation improves CAR-T cell efficacy in preclinical models.\",\n      \"method\": \"MAP4K1 KO mice, CAR-T cell tumor models, PROTAC degradation, pharmacological inhibition\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse models with multiple tumor models, CAR-T functional assays, multiple pharmacological modalities\",\n      \"pmids\": [\"32860752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MAP4K1 (HPK1) negatively regulates RLR antiviral signaling by interacting with TBK1 (identified by yeast two-hybrid) and promoting K48-linked ubiquitination and proteasomal degradation of TBK1/IKKε via the E3 ubiquitin ligase DTX4; MAP4K1 overexpression inhibits IFN-β production after RNA virus infection, while knockdown/knockout has the opposite effect; DTX4 knockdown abrogates TBK1 ubiquitination.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, overexpression and knockdown/knockout, ubiquitination assay (K48-linkage), proteasome inhibitor treatment\",\n      \"journal\": \"Microbiology spectrum\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — yeast two-hybrid initial identification, co-IP, ubiquitination assay with linkage specificity, DTX4 epistasis; multiple orthogonal methods\",\n      \"pmids\": [\"34908452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"An allosteric HPK1 inhibitor binds preferentially to unphosphorylated (inactive) full-length HPK1 (>24-fold vs. active HPK1), is non-competitive with ATP, requires domains outside the isolated kinase domain, and attenuates kinase autophosphorylation, revealing an allosteric pocket encompassing residues within and outside the kinase domain.\",\n      \"method\": \"Kinase cascade assay, ATP-competition assay, isolated kinase domain binding assay, biochemical binding assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic biochemical characterization of allosteric binding mode, domain requirement established by direct comparison\",\n      \"pmids\": [\"34608799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The HPK1 citron homology domain (CHD) adopts a seven-bladed β-propellor fold that directly binds to the kinase domain (KD); CHD-KD interaction negatively regulates kinase activity; CHD provides protein stability in cells and contributes to docking of the substrate SLP76.\",\n      \"method\": \"X-ray crystallography (CHD structure), hydrogen-deuterium exchange mass spectrometry, mutagenesis, biochemical binding assays, functional kinase assays, cellular stability assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus HDX-MS plus mutagenesis with functional correlation; multiple orthogonal methods in single study\",\n      \"pmids\": [\"38697971\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HPK1 is aberrantly overexpressed in dysfunctional NK cells; conditional HPK1 overexpression in NK cells exacerbates melanoma lung metastasis; MAP4K1-deficient mice are resistant to metastasis; mechanistically HPK1 restrains NK cell cytotoxicity and expansion via activating receptors; TGF-β1 upregulates HPK1 in NK cells.\",\n      \"method\": \"Conditional NK cell-specific HPK1 overexpression mouse model, MAP4K1-deficient mice, tumor metastasis assays, NK cytotoxicity assays, activating receptor signaling assays\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional gain-of-function and KO mouse models with specific cellular phenotype readouts\",\n      \"pmids\": [\"38828677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In glioblastoma cells, MAP4K1 loss down-regulates membrane-bound IL-18R and IL-6R by inhibiting the PI3K-AKT pathway; MAP4K1 restoration rescues IL-18R/IL-6R expression and proliferative responses to IL-18, revealing a cancer cell-intrinsic oncogenic role via the IL-18/IL-18R/PI3K-AKT pathway.\",\n      \"method\": \"MAP4K1 siRNA knockdown, MAP4K1 restoration rescue, transcriptome analysis, PI3K-AKT pathway western blotting, IL-18 stimulation assays\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — KD and rescue experiment, pathway-level western blotting; single lab\",\n      \"pmids\": [\"37734869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HPK1 enhances NF-κB/STAT3/p38-MAPK pathways and gasdermin D cleavage in neutrophils, promoting neutrophil hyperactivation; HPK1 promotes mobilization of CXCR2high bone marrow neutrophils after ischemic stroke; HPK1 loss or pharmacological inhibition reduces neutrophil hyperactivation, NET aggregation, and post-stroke lung/neurological injury.\",\n      \"method\": \"HPK1-deficient mice, pharmacological HPK1 inhibition, neutrophil activation assays, LPS-stimulated pathway analysis, mouse AIS model\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse and pharmacological inhibition, pathway-level mechanistic readouts; single lab\",\n      \"pmids\": [\"40169896\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MAP4K1 (HPK1) is a hematopoietic-restricted Ste20-related serine/threonine kinase that functions as a negative immune checkpoint: it is activated downstream of TCR/BCR engagement (via adaptors including Grb2, SLP-76, Gads/Mona, ADAP, Clnk, and Crk) and by PGE2 via a PKA-dependent mechanism (phosphorylating Ser171); activated HPK1 phosphorylates CARMA1 (at S549/S551/S552) to initially promote NF-κB and phosphorylates BLNK (T152) to trigger its ubiquitination and degradation, dampening BCR signaling; it signals through a MEKK1/MLK3→MKK4/SEK1→JNK cascade, and during apoptosis is cleaved by caspase-3 at Asp385, generating an N-terminal fragment with enhanced constitutive kinase activity (sustaining JNK/Bad phosphorylation) and a C-terminal HPK1-C fragment that dominantly inhibits NF-κB by sequestering the IKK complex; structurally, the kinase domain undergoes activation-loop-driven trans-regulation via dimer formation, and the C-terminal citron homology domain folds as a β-propellor that binds the kinase domain to restrain activity and dock substrate SLP76; additionally, HPK1 negatively regulates innate antiviral signaling by recruiting the E3 ligase DTX4 to promote K48-linked ubiquitination and proteasomal degradation of TBK1/IKKε, and competes with ADAP for SLP-76 binding to dampen Rap1-mediated integrin activation in both T cells and B cells.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MAP4K1 (HPK1) is a hematopoietic-restricted Ste20-family serine/threonine kinase that functions as a central negative regulator of antigen receptor signaling, integrin activation, and innate immune responses. Activated downstream of TCR/BCR engagement via adaptors SLP-76, BLNK, Grb2, Gads, Crk, and Clnk, and independently by PGE2 through PKA-mediated phosphorylation of Ser171, HPK1 signals through MEKK1/TAK1/MLK3→MKK4→JNK and IKK→NF-κB cascades, while attenuating receptor signaling by phosphorylating BLNK (T152) to trigger its ubiquitination and degradation, competing with ADAP for SLP-76 binding to dampen Rap1/integrin activation, and recruiting DTX4 to promote K48-linked ubiquitination of TBK1/IKKε thereby suppressing type I interferon production [PMID:8824585, PMID:10795738, PMID:22334673, PMID:20957749, PMID:34908452]. During apoptosis, caspase-3 cleavage at Asp385 generates a constitutively active N-terminal kinase fragment that sustains JNK/Bad signaling and a C-terminal fragment that sequesters the IKK complex to inhibit NF-κB and promote activation-induced cell death [PMID:10602493, PMID:11278403, PMID:16341093]. Structurally, the kinase domain forms an inactive dimer regulated by activation-loop trans-phosphorylation, while the C-terminal citron homology domain adopts a β-propeller fold that restrains kinase activity and docks substrate SLP-76; genetic ablation of HPK1 enhances anti-tumor immunity by preventing T cell exhaustion and augmenting NK cell cytotoxicity [PMID:31018963, PMID:38697971, PMID:32860752, PMID:38828677].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Identifying HPK1 as a novel Ste20-family kinase that specifically activates the JNK/SAPK pathway via MEKK1 and MLK3→SEK1/MKK4 established the initial signaling cascade framework and distinguished it from Rac/Cdc42-dependent MAP4Ks.\",\n      \"evidence\": \"Overexpression kinase assays, direct in vitro MEKK1 phosphorylation, dominant-negative epistasis in COS cells\",\n      \"pmids\": [\"8824585\", \"9003777\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation site on MEKK1 not identified\", \"Physiological cell type and upstream stimulus not established\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstration that TAK1 functions between HPK1 and MKK4 refined the kinase cascade hierarchy, while identification of Grb2 SH3 domain binding to HPK1 proline-rich motifs revealed the first mechanism for receptor-proximal recruitment of HPK1.\",\n      \"evidence\": \"Dominant-negative epistasis placing TAK1 between HPK1 and MKK4; in vitro SH3 binding and co-IP after EGF stimulation\",\n      \"pmids\": [\"9278437\", \"9346925\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TAK1 is a direct HPK1 substrate not shown\", \"Functional relevance in hematopoietic cells not yet tested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Discovery that caspase-3 cleaves HPK1 at Asp385 during apoptosis, generating a constitutively active kinase fragment and an adaptor-binding-deficient C-terminal fragment, revealed a proteolytic switch that bifurcates HPK1 signaling into pro-apoptotic JNK and anti-NF-κB outputs.\",\n      \"evidence\": \"In vitro cleavage by recombinant caspase-3, D385A mutagenesis, co-IP loss of Grb2/Crk binding\",\n      \"pmids\": [\"10602493\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological consequence of cleavage not yet demonstrated\", \"Whether cleavage occurs during normal T cell activation unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing that HPK1 is activated by TCR/BCR engagement via Src/Syk kinases and adaptors SLP-76/BLNK/LAT, and that kinase-dead HPK1 potentiates TCR signaling, defined HPK1 as a negative feedback regulator of antigen receptor responses.\",\n      \"evidence\": \"HPK1 kinase activity assays after receptor engagement, kinase-dead dominant-negative effects on AP-1/ERK, co-IP with adaptors\",\n      \"pmids\": [\"10795738\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrates mediating negative regulation not identified\", \"In vivo consequence in knockout animals not yet shown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Mechanistic dissection showed that full-length HPK1 activates NF-κB through IKKβ independently of JNK, while the caspase-generated C-terminal fragment dominantly inhibits NF-κB by sequestering the IKK complex, establishing dual roles for intact versus cleaved HPK1.\",\n      \"evidence\": \"Dominant-negative IKKβ and SEK1 epistasis, truncation analysis, NF-κB reporter assays; endogenous IKK co-IP, siRNA, HPK1-C transgenic mice (2005 follow-up)\",\n      \"pmids\": [\"11278403\", \"16341093\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct HPK1 phosphorylation of IKK subunits not demonstrated\", \"Stoichiometry of HPK1-C sequestration in vivo unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of additional SH3-containing adaptors Grap2/MONA/Gads and Clnk as HPK1-binding partners expanded the upstream receptor-proximal signaling network connecting immunoreceptors to HPK1 activation.\",\n      \"evidence\": \"Co-IP from Jurkat cells (Grap2), yeast two-hybrid plus co-IP (Clnk), kinase-dead epistasis on IL-2 promoter\",\n      \"pmids\": [\"11313918\", \"11509653\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of each adaptor not dissected in primary cells\", \"Whether adaptors are redundant or pathway-specific unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of PKA-mediated phosphorylation of Ser171 as the mechanism for PGE2-induced HPK1 activation defined a tyrosine-kinase-independent activation route, linking prostaglandin/cAMP signaling to HPK1 in immunosuppressive contexts.\",\n      \"evidence\": \"S171A mutagenesis abolishing PGE2-induced activation, PKA-deficient S49 cell validation, pharmacological dissection\",\n      \"pmids\": [\"17895239\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PKA directly phosphorylates S171 in vitro not shown with purified components\", \"In vivo relevance to tumor microenvironment PGE2 not tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identification of CARMA1 as a direct HPK1 substrate (phosphorylated at S549/S551/S552) required for TCR-induced NF-κB activation provided the first substrate-level mechanism for HPK1's role in NF-κB signaling.\",\n      \"evidence\": \"In vitro kinase assay with CARMA1 linker, site-directed mutagenesis, rescue in CARMA1-deficient T cells\",\n      \"pmids\": [\"19706536\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CARMA1 phosphorylation is activating or priming for negative regulation not fully resolved\", \"Relationship to HPK1's overall negative regulatory role on T cells needs clarification\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery that HPK1 competes with ADAP for SLP-76 binding to dampen Rap1 activation and LFA-1-mediated integrin adhesion in both T and B cells established HPK1 as a negative regulator of inside-out integrin signaling.\",\n      \"evidence\": \"HPK1-deficient mouse T and B cells, competitive co-IP, Rap1-GTP pulldown, ICAM-1 adhesion assays\",\n      \"pmids\": [\"20957749\", \"20824186\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HPK1 kinase activity or scaffolding is required for this competition not resolved\", \"Relative importance in vivo during immune responses not established\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstration that HPK1 phosphorylates BLNK at T152, triggering 14-3-3 binding and K48-linked ubiquitination/degradation of BLNK, provided the molecular mechanism for HPK1-mediated attenuation of BCR signaling.\",\n      \"evidence\": \"In vitro kinase assay, HPK1-KO B cells, mass spectrometry of ubiquitination sites, site-directed mutagenesis\",\n      \"pmids\": [\"22334673\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase responsible for BLNK ubiquitination not identified\", \"Whether analogous phosphodegron mechanism operates for SLP-76 in T cells unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Crystal structures of the HPK1 kinase domain in non-phosphorylated, phosphorylated, and phosphomimetic states revealed that inactive HPK1 forms a dimer with activation loops blocking partner active sites, and activation-loop phosphorylation disrupts this dimer, establishing the structural basis for trans-regulatory autoinhibition.\",\n      \"evidence\": \"X-ray crystallography at 2.17–3.00 Å resolution in multiple phosphorylation states\",\n      \"pmids\": [\"31018963\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length HPK1 structure not determined\", \"How C-terminal domains modulate dimerization unknown at this point\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Genetic ablation and pharmacological inhibition/PROTAC degradation of HPK1 enhanced anti-tumor T cell responses via the NF-κB–Blimp1 axis, validating HPK1 as an immune checkpoint whose loss prevents T cell exhaustion in tumor models.\",\n      \"evidence\": \"MAP4K1 KO mice, CAR-T cell tumor models, PROTAC degradation, pharmacological inhibition\",\n      \"pmids\": [\"32860752\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Optimal therapeutic window and potential autoimmune consequences not addressed\", \"Whether kinase activity or scaffolding drives exhaustion not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"HPK1 was shown to negatively regulate innate antiviral signaling by recruiting E3 ligase DTX4 to promote K48-linked ubiquitination and proteasomal degradation of TBK1/IKKε, extending HPK1's negative regulatory role beyond adaptive to innate immunity.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP, ubiquitination assay with K48-linkage specificity, DTX4 knockdown epistasis, KO cells\",\n      \"pmids\": [\"34908452\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical reconstitution of HPK1-DTX4-TBK1 trimeric complex not performed\", \"Whether HPK1 kinase activity is required for DTX4 recruitment not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Structural determination of the citron homology domain (CHD) as a β-propeller that binds the kinase domain to restrain activity and dock SLP-76 resolved how the C-terminal region autoinhibits HPK1 and mediates substrate engagement, complementing earlier kinase domain structures.\",\n      \"evidence\": \"X-ray crystallography of CHD, HDX-MS for KD-CHD interaction, mutagenesis, cellular stability assays\",\n      \"pmids\": [\"38697971\", \"38697971\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length HPK1 structure with CHD–KD interaction at atomic resolution still lacking\", \"Whether allosteric inhibitors target the CHD-KD interface not determined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"HPK1 was identified as a negative regulator of NK cell cytotoxicity; conditional overexpression exacerbated melanoma metastasis while KO conferred resistance, broadening HPK1's immune checkpoint role beyond T and B cells to NK cells, with TGF-β1 identified as an upstream inducer.\",\n      \"evidence\": \"NK cell-specific conditional HPK1 overexpression and KO mice, tumor metastasis models, NK cytotoxicity assays\",\n      \"pmids\": [\"38828677\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrates mediating NK cell suppression not identified\", \"Whether HPK1 operates through same SLP-76/integrin axis in NK cells unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full-length HPK1 structure capturing CHD-KD intramolecular regulation, identification of the E3 ligase for BLNK degradation, whether kinase activity versus scaffolding drives T cell exhaustion, and whether HPK1 inhibition triggers autoimmunity in therapeutic settings.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Full-length HPK1 atomic structure not solved\", \"Kinase-dependent vs. scaffolding-dependent functions not genetically separated in vivo\", \"In vivo autoimmune consequences of chronic HPK1 inhibition not systematically evaluated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 18, 21]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [7, 19, 20, 25, 26, 29]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [8, 13, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [7, 13, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 1, 2, 6, 8, 18, 25]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 19, 21, 25, 26, 29]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5, 14, 16]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 6, 8, 18, 25]}\n    ],\n    \"complexes\": [\n      \"IKK complex (via HPK1-C sequestration)\"\n    ],\n    \"partners\": [\n      \"MEKK1\",\n      \"SLP76\",\n      \"BLNK\",\n      \"GRB2\",\n      \"CRK\",\n      \"TBK1\",\n      \"DTX4\",\n      \"CARMA1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}